Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nal-IRI, 5-FU, and Rucaparib in GI Cancers
NCT03337087Phase 2Active, not recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Nov 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rucaparib in pancreatic adenocarcinoma (PDAC), colorectal cancer (CRC), gastroesophageal junction adenocarcinoma, biliary tract carcinoma (BTC), sponsored by Academic and Community Cancer Research United. Started Nov 2018; status: active, not recruiting.
02
Drugs
rucaparib
03
Conditions
pancreatic adenocarcinoma (PDAC)colorectal cancer (CRC)gastroesophageal junction adenocarcinomabiliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT03337087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337087.